메뉴 건너뛰기




Volumn 3, Issue 1, 2014, Pages

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

Author keywords

Anti CTLA4; Checkpoint blockade; Immunotherapy; Local therapy; Pancreatic cancer

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FC RECEPTOR;

EID: 84899106840     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27614     Document Type: Article
Times cited : (73)

References (34)
  • 1
    • 84855792427 scopus 로고    scopus 로고
    • Cancer statistics, 2012
    • PMID:22237781
    • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138.
    • (2012) CA Cancer J Clin , vol.62 , pp. 10-29
    • Siegel, R.1    Naishadham, D.2    Jemal, A.3
  • 2
    • 84872066969 scopus 로고    scopus 로고
    • Current concepts and novel targets in advanced pancreatic cancer
    • PMID:23112132
    • Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013; 62:317-26; PMID:23112132; http://dx.doi.org/10.1136/gutjnl-2012-303588.
    • (2013) Gut , vol.62 , pp. 317-326
    • Michl, P.1    Gress, T.M.2
  • 3
    • 84866450512 scopus 로고    scopus 로고
    • The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion
    • PMID:22969725
    • Evans A, Costello E. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front Physiol 2012; 3:270; PMID:22969725.
    • (2012) Front Physiol , vol.3 , pp. 270
    • Evans, A.1    Costello, E.2
  • 4
    • 84871211965 scopus 로고    scopus 로고
    • Monoclonal antibodies and other targeted therapies for pancreatic cancer
    • PMID:23187854
    • Cinar P, Tempero MA. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J 2012; 18:653-64; PMID:23187854; http://dx.doi. org/10.1097/PPO.0b013e3182758985.
    • (2012) Cancer J , vol.18 , pp. 653-664
    • Cinar, P.1    Tempero, M.A.2
  • 5
    • 0035056017 scopus 로고    scopus 로고
    • CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy
    • PMID:11244047
    • Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19:565-94; PMID:11244047; http://dx.doi.org/10.1146/annurev.immunol.19.1.565.
    • (2001) Annu Rev Immunol , vol.19 , pp. 565-594
    • Chambers, C.A.1    Kuhns, M.S.2    Egen, J.G.3    Allison, J.P.4
  • 6
    • 33745851479 scopus 로고    scopus 로고
    • CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    • PMID:16778987
    • Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116:1935-45; PMID:16778987; http://dx.doi.org/10.1172/JCI27745.
    • (2006) J Clin Invest , vol.116 , pp. 1935-1945
    • Quezada, S.A.1    Peggs, K.S.2    Curran, M.A.3    Allison, J.P.4
  • 7
    • 24944459890 scopus 로고    scopus 로고
    • Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
    • PMID:16087944
    • Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-53; PMID:16087944; http://dx.doi.org/10.1200/JCO.2005.06.205.
    • (2005) J Clin Oncol , vol.23 , pp. 6043-6053
    • Attia, P.1    Phan, G.Q.2    Maker, A.V.3    Robinson, M.R.4    Quezado, M.M.5    Yang, J.C.6    Sherry, R.M.7    Topalian, S.L.8    Kammula, U.S.9    Royal, R.E.10
  • 8
    • 77950258677 scopus 로고    scopus 로고
    • Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival
    • PMID:20143434
    • Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116:1767-75; PMID:20143434; http://dx.doi.org/10.1002/cncr.24951.
    • (2010) Cancer , vol.116 , pp. 1767-1775
    • Ku, G.Y.1    Yuan, J.2    Page, D.B.3    Schroeder, S.E.4    Panageas, K.S.5    Carvajal, R.D.6    Chapman, P.B.7    Schwartz, G.K.8    Allison, J.P.9    Wolchok, J.D.10
  • 10
    • 79958844438 scopus 로고    scopus 로고
    • Ipilimumab: first global approval
    • PMID:21668044
    • Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs 2011; 71:1093-104; PMID:21668044; http://dx.doi. org/10.2165/11594010-000000000-00000.
    • (2011) Drugs , vol.71 , pp. 1093-1104
    • Cameron, F.1    Whiteside, G.2    Perry, C.3
  • 11
    • 77958050577 scopus 로고    scopus 로고
    • Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma
    • PMID:20842054
    • Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33:828-33; PMID:20842054; http://dx.doi. org/10.1097/CJI.0b013e3181eec14c.
    • (2010) J Immunother , vol.33 , pp. 828-833
    • Royal, R.E.1    Levy, C.2    Turner, K.3    Mathur, A.4    Hughes, M.5    Kammula, U.S.6    Sherry, R.M.7    Topalian, S.L.8    Yang, J.C.9    Lowy, I.10
  • 12
    • 84883207410 scopus 로고    scopus 로고
    • Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
    • PMID:23924790
    • Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr., Donehower RC, Jaffee EM, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36:382-9; PMID:23924790; http://dx.doi.org/10.1097/CJI.0b013e31829fb7a2.
    • (2013) J Immunother , vol.36 , pp. 382-389
    • Le, D.T.1    Lutz, E.2    Uram, J.N.3    Sugar, E.A.4    Onners, B.5    Solt, S.6    Zheng, L.7    Diaz Jr., L.A.8    Donehower, R.C.9    Jaffee, E.M.10
  • 13
    • 84886427186 scopus 로고    scopus 로고
    • Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects
    • PMID:23788581
    • Fransen MF, van der Sluis TC, Ossendorp F, Arens R, Melief CJ. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res 2013; 19:5381-9; PMID:23788581; http://dx.doi.org/10.1158/1078-0432.CCR-12-0781.
    • (2013) Clin Cancer Res , vol.19 , pp. 5381-5389
    • Fransen, M.F.1    van der Sluis, T.C.2    Ossendorp, F.3    Arens, R.4    Melief, C.J.5
  • 14
    • 34250871751 scopus 로고    scopus 로고
    • Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses
    • PMID:17575163
    • Tuve S, Chen BM, Liu Y, Cheng TL, Touré P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 2007; 67:5929-39; PMID:17575163; http://dx.doi.org/10.1158/0008-5472.CAN-06-4296.
    • (2007) Cancer Res , vol.67 , pp. 5929-5939
    • Tuve, S.1    Chen, B.M.2    Liu, Y.3    Cheng, T.L.4    Touré, P.5    Sow, P.S.6    Feng, Q.7    Kiviat, N.8    Strauss, R.9    Ni, S.10
  • 15
    • 44249090471 scopus 로고    scopus 로고
    • Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity
    • PMID:18236040
    • Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother 2008; 57:1263-70; PMID:18236040; http://dx.doi. org/10.1007/s00262-008-0451-3.
    • (2008) Cancer Immunol Immunother , vol.57 , pp. 1263-1270
    • Simmons, A.D.1    Moskalenko, M.2    Creson, J.3    Fang, J.4    Yi, S.5    VanRoey, M.J.6    Allison, J.P.7    Jooss, K.8
  • 16
    • 84884271914 scopus 로고    scopus 로고
    • Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
    • PMID:23897981
    • Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210:1695-710; PMID:23897981; http://dx.doi.org/10.1084/jem.20130579.
    • (2013) J Exp Med , vol.210 , pp. 1695-1710
    • Simpson, T.R.1    Li, F.2    Montalvo-Ortiz, W.3    Sepulveda, M.A.4    Bergerhoff, K.5    Arce, F.6    Roddie, C.7    Henry, J.Y.8    Yagita, H.9    Wolchok, J.D.10
  • 17
    • 84884229186 scopus 로고    scopus 로고
    • Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
    • PMID:23897982
    • Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013; 210:1685-93; PMID:23897982; http://dx.doi.org/10.1084/jem.20130573.
    • (2013) J Exp Med , vol.210 , pp. 1685-1693
    • Bulliard, Y.1    Jolicoeur, R.2    Windman, M.3    Rue, S.M.4    Ettenberg, S.5    Knee, D.A.6    Wilson, N.S.7    Dranoff, G.8    Brogdon, J.L.9
  • 18
    • 84878936788 scopus 로고    scopus 로고
    • Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
    • Selby MJ. E.J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., Korman A.J. Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. Cancer Immunology Research 2013; 1:32-42; http://dx.doi.org/10.1158/2326-6066.CIR-13-0013.
    • (2013) Cancer Immunology Research , vol.1 , pp. 32-42
    • Selby, M.J.E.J.J.1    Quigley, M.2    Henning, K.A.3    Chen, T.4    Srinivasan, M.5    Korman, A.J.6
  • 19
    • 84886405297 scopus 로고    scopus 로고
    • Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity
    • PMID:23965900
    • Marabelle A, Kohrt H, Levy R. Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res 2013; 19:5261-3; PMID:23965900; http://dx.doi.org/10.1158/1078-0432.CCR-13-1923.
    • (2013) Clin Cancer Res , vol.19 , pp. 5261-5263
    • Marabelle, A.1    Kohrt, H.2    Levy, R.3
  • 20
    • 84899076438 scopus 로고    scopus 로고
    • Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer
    • Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res 2014; 2: 80; http://dx.doi.org/10.1158/2326-6066. CIR-13-0067.
    • (2014) Cancer Immunol Res , vol.2 , pp. 80
    • Sandin, L.C.1    Orlova, A.2    Gustafsson, E.3    Ellmark, P.4    Tolmachev, V.5    Tötterman, T.H.6    Mangsbo, S.M.7
  • 21
    • 77954938867 scopus 로고    scopus 로고
    • Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy
    • PMID:20445343
    • Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010; 33:225-35; PMID:20445343; http://dx.doi.org/10.1097/CJI.0b013e3181c01fcb.
    • (2010) J Immunother , vol.33 , pp. 225-235
    • Mangsbo, S.M.1    Sandin, L.C.2    Anger, K.3    Korman, A.J.4    Loskog, A.5    Tötterman, T.H.6
  • 22
    • 0035903324 scopus 로고    scopus 로고
    • Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
    • PMID:11560997
    • Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194:823-32; PMID:11560997; http://dx.doi.org/10.1084/jem.194.6.823.
    • (2001) J Exp Med , vol.194 , pp. 823-832
    • Sutmuller, R.P.1    van Duivenvoorde, L.M.2    van Elsas, A.3    Schumacher, T.N.4    Wildenberg, M.E.5    Allison, J.P.6    Toes, R.E.7    Offringa, R.8    Melief, C.J.9
  • 23
    • 51349165526 scopus 로고    scopus 로고
    • CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
    • PMID:18523152
    • Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008; 112:1175-83; PMID:18523152; http://dx.doi. org/10.1182/blood-2007-11-125435.
    • (2008) Blood , vol.112 , pp. 1175-1183
    • Kavanagh, B.1    O'Brien, S.2    Lee, D.3    Hou, Y.4    Weinberg, V.5    Rini, B.6    Allison, J.P.7    Small, E.J.8    Fong, L.9
  • 24
    • 77749279776 scopus 로고    scopus 로고
    • PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
    • PMID:20160101
    • Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107:4275-80; PMID:20160101; http://dx.doi.org/10.1073/pnas.0915174107.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 4275-4280
    • Curran, M.A.1    Montalvo, W.2    Yagita, H.3    Allison, J.P.4
  • 25
    • 79955785050 scopus 로고    scopus 로고
    • Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production
    • PMID:21559358
    • Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011; 6:e19499; PMID:21559358; http://dx.doi.org/10.1371/journal. pone.0019499.
    • (2011) PLoS One , vol.6
    • Curran, M.A.1    Kim, M.2    Montalvo, W.3    Al-Shamkhani, A.4    Allison, J.P.5
  • 27
    • 0034679567 scopus 로고    scopus 로고
    • Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation
    • PMID:10899916
    • Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192:295-302; PMID:10899916; http://dx.doi. org/10.1084/jem.192.2.295.
    • (2000) J Exp Med , vol.192 , pp. 295-302
    • Read, S.1    Malmström, V.2    Powrie, F.3
  • 28
    • 0037446531 scopus 로고    scopus 로고
    • Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells
    • PMID:12682220
    • Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003; 170:3939-43; PMID:12682220.
    • (2003) J Immunol , vol.170 , pp. 3939-3943
    • Mottet, C.1    Uhlig, H.H.2    Powrie, F.3
  • 29
    • 77249137663 scopus 로고    scopus 로고
    • Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease
    • PMID:19936899
    • Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010; 30:80-9; PMID:19936899; http://dx.doi. org/10.1007/s10875-009-9345-1.
    • (2010) J Clin Immunol , vol.30 , pp. 80-89
    • Eastaff-Leung, N.1    Mabarrack, N.2    Barbour, A.3    Cummins, A.4    Barry, S.5
  • 30
    • 75249100054 scopus 로고    scopus 로고
    • Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
    • PMID:20004617
    • Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx.doi.org/10.1016/S1470-2045(09)70334-1.
    • (2010) Lancet Oncol , vol.11 , pp. 155-164
    • Wolchok, J.D.1    Neyns, B.2    Linette, G.3    Negrier, S.4    Lutzky, J.5    Thomas, L.6    Waterfield, W.7    Schadendorf, D.8    Smylie, M.9    Guthrie Jr., T.10
  • 31
    • 84876678701 scopus 로고    scopus 로고
    • Lowdose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer
    • PMID:23233419
    • Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, Umansky V, Bazhin AV. Lowdose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 2013; 133:98-107; PMID:23233419; http://dx.doi.org/10.1002/ijc.27990.
    • (2013) Int J Cancer , vol.133 , pp. 98-107
    • Shevchenko, I.1    Karakhanova, S.2    Soltek, S.3    Link, J.4    Bayry, J.5    Werner, J.6    Umansky, V.7    Bazhin, A.V.8
  • 32
    • 34248172651 scopus 로고    scopus 로고
    • CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo
    • PMID:17315190
    • Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P, Sutmuller RP, Adema GJ. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007; 121:95-105; PMID:17315190; http://dx.doi.org/10.1002/ijc.22607.
    • (2007) Int J Cancer , vol.121 , pp. 95-105
    • Grauer, O.M.1    Nierkens, S.2    Bennink, E.3    Toonen, L.W.4    Boon, L.5    Wesseling, P.6    Sutmuller, R.P.7    Adema, G.J.8
  • 33
    • 75149139044 scopus 로고    scopus 로고
    • Combination of CTLassociated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer
    • PMID:20384858
    • Saha A, Chatterjee SK. Combination of CTLassociated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand J Immunol 2010; 71:70-82; PMID:20384858; http://dx.doi. org/10.1111/j.1365-3083.2009.02355.x.
    • (2010) Scand J Immunol , vol.71 , pp. 70-82
    • Saha, A.1    Chatterjee, S.K.2
  • 34
    • 68149155982 scopus 로고    scopus 로고
    • Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    • PMID:19581407
    • Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206:1717-25; PMID:19581407; http://dx.doi.org/10.1084/jem.20082492.
    • (2009) J Exp Med , vol.206 , pp. 1717-1725
    • Peggs, K.S.1    Quezada, S.A.2    Chambers, C.A.3    Korman, A.J.4    Allison, J.P.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.